Cited by 128Cardiac Imaging and DiagnosticsAdenosine and Purinergic SignalingMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Initial Clinical Experience With Regadenoson, a Novel Selective A2AAgonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging

Open access

Hendel, Robert C., Bateman, Timothy M., Cerqueira, Manuel D., Iskandrian, Ami E., Leppo, Jeffrey A., Blackburn, Brent, Mahmarian, John J.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.05.097

Open this paper in CoChat — free account

Abstract

Objectives Regadenoson, a selective A2A adenosine receptor agonist, was evaluated for tolerability and effectiveness as a pharmacological stress agent for detecting reversible myocardial hypoperfusion when combined with single-photon emission computed tomography (SPECT).Background Adenosine and dipyridamole are nonselective adenosine agonists currently used as pharmacologic stressors. Despite proven safety, these agents often cause undesirable side effects and require a continuous infusion.Methods This Phase II, multicenter, open-label trial was conducted in 36 patients who had demonstrated ischemia on a 6-min adenosine SPECT imaging study within the previous 2 to 46 days. Patients received regadenoson as a rapid intravenous bolus dose of 400 microg (n = 18) or 500 microg (n = 18). The radiopharmaceutical was then delivered within one minute. The SPECT images were acquired in a standard manner and uniformly processed at a central laboratory. Regadenoson and adenosine studies were presented in random order and interpreted blindly with a 17-segment model by three observers. Additionally, quantitative analysis was performed with 4D-MSPECT software (University of Michigan, Ann Arbor, Michigan).Results Overall agreement for the presence of reversible hypoperfusion was 86%. The 400-mug dose was better tolerated. Overall, regadenoson was well-tolerated; side effects (e.g., chest discomfort, flushing, dyspnea) were generally mild in severity and self-limiting. High-grade atrioventricular block and bronchospasm were not observed.Conclusions Regadenoson is well-tolerated and seems as effective as adenosine for detecting and quantifying the extent of hypoperfusion observed with SPECT perfusion imaging. Phase III clinical trials are now underway, given the promise of regadenoson's reduced side effects and simplicity of bolus administration.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.05.097

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart
Cerqueira, M. D., Weissman, N. J., Dilsizian, V., Jacobs, A. K., Kaul, S., Laskey, W. K., Pennell, D. J., Rumberger, J. A., Ryan, T., & Verani, M. S. (2002) · Circulation · doi:10.1161/hc0402.102975 · Cited by 7,043
Self-citation
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologie coronary vasodilatation
Gould, K. L. (1978) · The American Journal of Cardiology · doi:10.1016/0002-9149(78)90165-0 · Cited by 460
Safety profile of adenosine stress perfusion imaging: Results from the adenoscan multicenter trial registry
Cerqueira, M. D., Verani, M. S., Schwaiger, M., Heo, J., & Iskandrian, A. S. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90424-3 · Cited by 459
Self-citation
Imaging guidelines for nuclear cardiology procedures
Port, S. C. (1999) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(99)90088-0 · Cited by 294
The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group.
Ranhosky, A., & Kempthorne‐Rawson, J. (1990) · Circulation · doi:10.1161/01.cir.81.4.1205 · Cited by 291
A 2A -Adenosine Receptor Reserve for Coronary Vasodilation
Shryock, J. C., Snowdy, S., Baraldi, P. G., Cacciari, B., Spalluto, G., Monopoli, A., Ongini, E., Baker, S. P., & Belardinelli, L. (1998) · Circulation · doi:10.1161/01.cir.98.7.711 · Cited by 199
The A2A Adenosine Receptor Mediates Coronary Vasodilation
Belardinelli, L., Shryock, J. C., Snowdy, S., Zhang, Y., Monopoli, A., Lozza, G., Ongini, E., Olsson, R. A., & Dennis, D. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37317-3 · Cited by 186
Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists
Gao, Z., Li, Z., Baker, S. P., Lasley, R. D., Meyer, S. M., Elzein, E. O., Palle, V. P., Zablocki, J. A., Blackburn, B. K., & Belardinelli, L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29370-8 · Cited by 124
Self-citation
Tachycardia Caused by A2A Adenosine Receptor Agonists Is Mediated by Direct Sympathoexcitation in Awake Rats
Dhalla, A. K., Wong, M.-Y., Wang, W., Biaggioni, I., & Belardinelli, L. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095323 · Cited by 111

Show all 17 references

Sorted by citations

Ischemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. D. L. G. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,468
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431
ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers
Henzlova, M. J., Duvall, W. L., Einstein, A. J., Travin, M. I., & Verberne, H. J. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0387-x · Cited by 700
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial
Iskandrian, A. E., Bateman, T. M., Belardinelli, L., Blackburn, B. K., Cerqueira, M. D., Hendel, R. C., Lieu, H. D., Mahmarian, J. J., Olmsted, A., Underwood, S. R., et al. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.06.114 · Cited by 347
Self-citation
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 285
Adenosine: An Old Drug Newly Discovered
Eltzschig, H. K., Warner, D. S., & Warner, M. A. A. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181b060f2 · Cited by 253
Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion Imaging
Cerqueira, M. D., Nguyen, P. K. P., Staehr, P., Underwood, S. R., & Iskandrian, A. E. (2008) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.02.003 · Cited by 243
Self-citation
Regadenoson: A New Myocardial Stress Agent
Jaroudi, W. A. A., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.089 · Cited by 219
Self-citation
Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans
Lieu, H. D., Shryock, J. C., von Mering, G. O., Gordi, T., Blackburn, B. K., Olmsted, A., Belardinelli, L., & Kerensky, R. A. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.02.016 · Cited by 140
Self-citation
Extracellular nucleotide and nucleoside signaling in vascular and blood disease
Idzko, M., Ferrari, D., Riegel, A.-K., & Eltzschig, H. K. (2014) · Blood · doi:10.1182/blood-2013-09-402560 · Cited by 135
Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial)
Thomas, G. S., Tammelin, B. R., Schiffman, G. L., Marquez, R., Rice, D. L., Milikien, D. A., & Mathur, V. S. (2008) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2008.02.013 · Cited by 119
Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world
Meimoun, P., & Tribouilloy, C. (2008) · European Journal of Echocardiography · doi:10.1093/ejechocard/jen004 · Cited by 118
Tachycardia Caused by A2A Adenosine Receptor Agonists Is Mediated by Direct Sympathoexcitation in Awake Rats
Dhalla, A. K., Wong, M.-Y., Wang, W., Biaggioni, I., & Belardinelli, L. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095323 · Cited by 111
Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology
McGeoch, R. J., & Oldroyd, K. G. (2008) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21307 · Cited by 100
Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance
Vasu, S., Bandettini, W. P., Hsu, L., Kellman, P., Leung, S., Mancini, C., Shanbhag, S. M., Wilson, J. R., Booker, O. J., & Arai, A. E. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-85 · Cited by 96
Direct comparison of rest and adenosine stress myocardial perfusion CT with rest and stress SPECT
Okada, D. R., Ghoshhajra, B. B., Blankstein, R., Rocha-Filho, J. A., Shturman, L. D., Rogers, I. S., Bezerra, H. G., Sarwar, A., Gewirtz, H., Hoffmann, U., et al. (2009) · Journal of Nuclear Cardiology · doi:10.1007/s12350-009-9156-z · Cited by 90
A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease
Prenner, B. M., Bukofzer, S., Behm, S., Feaheny, K., & McNutt, B. E. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9547-4 · Cited by 81
Regadenoson Versus Dipyridamole Hyperemia for Cardiac PET Imaging
Johnson, N. P., & Gould, K. L. (2015) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.11.016 · Cited by 81
Selective adenosine agonists and myocardial perfusion imaging
Zoghbi, G. J., & Iskandrian, A. E. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9474-9 · Cited by 71
Self-citation
Nuclear Cardiology: Present and Future
Russell, R. R., & Zaret, B. L. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.05.002 · Cited by 64
SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability
Beller, G., & Heede, R. C. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9290-2 · Cited by 59
American Society of Nuclear Cardiology review of the ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI)
Ward, R. P., Al-Mallah, M. H., Grossman, G. B., Hansen, C. L., Hendel, R. C., Kerwin, T. C., McCallister, B. D., Mehta, R., Polk, D. M., Tilkemeier, P. L., et al. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.10.001 · Cited by 58
Self-citation
Advances in Pharmacologic Stress Agents: Focus on Regadenoson
Johnson, S. G., & Peters, S. (2010) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.109.065581 · Cited by 55
Current Methods of Pharmacologic Stress Testing and the Potential Advantages of New Agents
Botvinick, E. H. (2009) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.108.057802 · Cited by 53
Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography
Gaemperli, O., Schepis, T., Koepfli, P., Siegrist, P. T., Fleischman, S., Nguyen, P., Olmsted, A., Wang, W., Lieu, H., & Kaufmann, P. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.014 · Cited by 52
Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients
Kwon, D. H., Cerqueira, M. D., Young, R., Houghtaling, P. L., Lieber, E. A., Menon, V., Brunken, R. C., & Jaber, W. A. (2010) · Journal of Nuclear Cardiology · doi:10.1007/s12350-010-9229-z · Cited by 51
Self-citation
The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation
Doukky, R., Rangel, M. O., Wassouf, M., Dick, R., Alqaid, A., & Morales‐Demori, R. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9654-2 · Cited by 49
Comparison of the Prognostic Value of Normal Regadenoson With Normal Adenosine Myocardial Perfusion Imaging With Propensity Score Matching
Iqbal, F. M., Hage, F. G., Ahmed, A., Dean, P., Raslan, S., Heo, J., & Iskandrian, A. E. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2012.04.009 · Cited by 48
Self-citation
Regadenoson
Garnock-Jones, K. P., & Curran, M. P. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/10489040-000000000-00000 · Cited by 48
Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET
Goudarzi, B., Fukushima, K., Bravo, P. E., Merrill, J., & Bengel, F. M. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1853-6 · Cited by 47
Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson
Bhave, N. M., Freed, B. H., Yodwut, C., Kolanczyk, D. M., Dill, K. E., Lang, R. M., Mor‐Avi, V., & Patel, A. R. (2012) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-14-89 · Cited by 45
Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy
Franco, R., Rivas‐Santisteban, R., Navarro, G., & Reyes‐Resina, I. (2021) · Cells · doi:10.3390/cells10112831 · Cited by 47
Safety and tolerability of regadenoson CMR
Nguyen, K., Bandettini, W. P., Shanbhag, S. M., Leung, S., Wilson, J. R., & Arai, A. E. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet278 · Cited by 44
A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease
Ananthasubramaniam, K., Weiss, R., McNutt, B. E., Klauke, B., Feaheny, K., & Bukofzer, S. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9508-3 · Cited by 43
Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients
Kazmirczak, F., Nijjar, P. S., Zhang, L. J., Hughes, A. N., Chen, K.-H. A., Okasha, O., Martin, C. M., Akçakaya, M., Farzaneh‐Far, A., & Shenoy, C. (2019) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-018-0515-2 · Cited by 43
Impact of regadenoson-induced myocardial creep on dynamic Rubidium-82 PET myocardial blood flow quantification
Koenders, S. S., van Dijk, J. D., Jager, P. L., Ottervanger, J. P., Slump, C. H., & van Dalen, J. A. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-019-01649-4 · Cited by 42
Automatic registration of misaligned CT attenuation correction maps in Rb-82 PET/CT improves detection of angiographically significant coronary artery disease
Slomka, P. J., Díaz‐Zamudio, M., Dey, D., Motwani, M., Brodov, Y., Choi, D. J., Hayes, S. W., Thomson, L., Friedman, J. D., Germano, G., et al. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-014-0060-9 · Cited by 41
Doppler Echocardiography Assessment of Coronary Microvascular Function in Patients With Angina and No Obstructive Coronary Artery Disease
Schrøder, J., & Prescott, E. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.723542 · Cited by 42
Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study
Tejani, F. H., Thompson, R. C., Kristy, R., & Bukofzer, S. (2014) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-014-0419-7 · Cited by 37
Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists
Cristalli, G., Cacciari, B., Ben, D. D., Lambertucci, C., Moro, S., Spalluto, G., & Volpini, R. (2006) · ChemMedChem · doi:10.1002/cmdc.200600193 · Cited by 37
Ex vivo and in vivo coronary ostial locations in humans
Knight, J., Kurtcuoglu, V., Muffly, K. E., Marshall, W. G., Stolzmann, P., Desbiolles, L. M., Seifert, B., Dimos Poulikakos, A., & Alkadhi, H. (2009) · Surgical and Radiologic Anatomy · doi:10.1007/s00276-009-0488-9 · Cited by 36
Pharmacologic stress myocardial perfusion imaging: A practical approach
Miyamoto, M. I., Vernotico, S. L., Majmundar, H., & Thomas, G. S. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.01.006 · Cited by 34
Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy
Brinkert, M., Reyes, E., Walker, S., Latus, K. A., Maenhout, A., Mizumoto, R., Nkomo, C., Standbridge, K., Wechalekar, K., & Underwood, S. R. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2619-0 · Cited by 32
Advances in pharmacologic agents in imaging: New A2A receptor agonists
Cerqueira, M. D. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0022-1 · Cited by 32
Self-citation
Caffeine Attenuates the Duration of Coronary Vasodilation and Changes in Hemodynamics Induced by Regadenoson (CVT-3146), a Novel Adenosine A2A Receptor Agonist
Zhao, G., Messina, E. J., Xu, X., Ochoa, M., Sun, H.-L., Leung, K., Shryock, J. C., Belardinelli, L., & Hintze, T. H. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318046f364 · Cited by 28
Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease
Reyes, E., Loong, C. Y., Wechalekar, K., Latus, K. A., Anagnostopoulos, C., & Underwood, S. R. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.07.013 · Cited by 28
Effects of Caffeine on Myocardial Blood Flow: A Systematic Review
van Dijk, R., Ties, D., Kuijpers, D., van der Harst, P., & Oudkerk, M. (2018) · Nutrients · doi:10.3390/nu10081083 · Cited by 28
Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance
Freed, B. H., Narang, A., Bhave, N. M., Czobor, P., Mor‐Avi, V., Zaran, E. R., Turner, K. M., Cavanaugh, K. P., Chandra, S., Tanaka, S. M., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-108 · Cited by 27
Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping
van Dijk, R., Kuijpers, D., Kaandorp, T. A. M., van Dijkman, P. R. M., Vliegenthart, R., van der Harst, P., & Oudkerk, M. (2017) · International journal of cardiac imaging · doi:10.1007/s10554-017-1157-4 · Cited by 27
The EXERRT trial: “EXErcise to Regadenoson in Recovery Trial”: A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol
Thomas, G. S., Cullom, S. J., Kitt, T. M., Feaheny, K., Ananthasubramaniam, K., Gropler, R. J., Jain, D., & Thompson, R. C. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-0813-3 · Cited by 24
Regadenoson pharmacologic stress for myocardial perfusion imaging: A three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise
Thompson, R. C., Patil, H., Thompson, E. C., Thomas, G. S., Al‐Amoodi, M., Kennedy, K. F., Bybee, K. A., McGhie, A. I., O’Keefe, J. H., Oakes, L., et al. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9660-4 · Cited by 24
Self-citation
Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis
Andrikopoulou, E., Morgan, C. J., Brice, L., Bajaj, N. S., Doppalapudi, H., Iskandrian, A. E., & Hage, F. G. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1081-y · Cited by 24
Self-citation
Comparison and Effectiveness of Regadenoson Versus Dipyridamole on Stress Electrocardiographic Changes During Positron Emission Tomography Evaluation of Patients With Hypertrophic Cardiomyopathy
Bravo, P. E., Pozios, I., Pinheiro, A. C., Merrill, J., Tsui, B. M. W., Wahl, R. L., Bengel, F. M., Abraham, M. R., & Abraham, T. P. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.038 · Cited by 23
Regadenoson
Palani, G., & Ananthasubramaniam, K. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e3182613db6 · Cited by 23
Effects of Adenosine and a Selective A2A Adenosine Receptor Agonist on Hemodynamic and Thallium-201 and Technetium-99m–SestaMIBI Biodistribution and Kinetics
Mekkaoui, C., Jadbabaie, F., Dione, D. P., Meoli, D. F., Kailasnath, P., Belardinelli, L., & Sinusas, A. J. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2009.06.013 · Cited by 19
Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry
Monmeneu, J. V., Gonzalez, M. P. G., López-Lereu, M. P., Ortega, L. H., & González, A. (2021) · International journal of cardiac imaging · doi:10.1007/s10554-021-02363-4 · Cited by 17
The evolving practice of nuclear cardiology: Results from the 2011 ASNC member survey
Tilkemeier, P. L., Green, J. L., Einstein, A. J., Fazel, R., Reames, P., & Shaw, L. J. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9624-8 · Cited by 16
New Trends in Radionuclide Myocardial Perfusion Imaging.
Hung, G., Wang, Y., Su, H.-Y., Hsieh, T., Ko, C., & Yen, R. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20150803a · Cited by 16
Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera
Brana, Q., Thibault, F., Courtehoux, M., Metrard, G., Ribeiro, M. J., Angoulvant, D., & Bailly, M. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02271-5 · Cited by 15
Impact of Selective Adenosine A2AReceptor Agonists on Cardiac Imaging
Miller, D. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.061 · Cited by 15
Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine
Grady, E. E., Barron, J. T., & Wagner, R. H. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9373-0 · Cited by 14
Pharmacological Preconditioning by Adenosine A2a Receptor Stimulation: Features of the Protected Liver Cell Phenotype
Alchera, E., Imarisio, C., Mandili, G., Merlin, S., Chandrashekar, B. R., Novelli, F., Follenzi, A., & Carini, R. (2015) · BioMed Research International · doi:10.1155/2015/286746 · Cited by 13
Regadenoson, a Novel Pharmacologic Stress Agent for Use in Myocardial Perfusion Imaging, Does Not Have a Direct Effect on the QT Interval in Conscious Dogs
Zhao, G., Serpllion, S., Shryock, J. C., Messina, E. J., Xu, X., Ochoa, M., Belardinelli, L., & Hintze, T. H. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31818e035b · Cited by 13
Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease
Kero, T., Saraste, A., Lagerqvist, B., Sörensen, J., Pikkarainen, E., Lubberink, M., & Knuuti, J. M. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02731-6 · Cited by 12
The Hydrazine Moiety in the Synthesis of Modified Nucleosides and Nucleotides
Guillou, A., Peyrottes, S., Vasseur, J., Mathé, C., & Smietana, M. (2024) · ChemMedChem · doi:10.1002/cmdc.202400234 · Cited by 11
Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A2A receptor agonist
Le, D. E., Bragadeesh, T., Zhao, Y., Wang, Y.-G., Zha, D., & Kaul, S. (2011) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ejechocard/jer232 · Cited by 11
Safety and tolerability of regadenoson for myocardial perfusion imaging – first Danish experience
Pape, M., Zacho, H. D., Aarøe, J., Jensen, S. E., & Petersen, L. J. (2016) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2016.1163415 · Cited by 11
Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking
Driessche, G. A. V. D., & Fourches, D. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0257-z · Cited by 12
Regadenoson
Bengalorkar, G. M., Bhuvana, K., Sarala, N., & Kumar, T. (2012) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.97177 · Cited by 11
Prevalence and significance of electrocardiographic changes and side effect profile of regadenoson compared with adenosine during myocardial perfusion imaging
Zahid, M., Kapila, A., Eagan, C. E., Yusko, D. A., Miller, E. D., & Missenda, C. D. (2013) · Journal of Cardiovascular Disease Research · doi:10.1016/j.jcdr.2012.10.001 · Cited by 10
Lessons From the Development of New Adenosine A2 Receptor Agonists
Udelson, J. E. (2008) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.03.003 · Cited by 10
Anatomical Distribution of Nucleoside System in the Human Brain and Implications for Therapy
Kovács, Z., & Dobolyi, Á. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3903-5_29 · Cited by 9
Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole
Friedman, M., Spalding, J. R., Kothari, S., Wu, Y., Gatt, E., & Boulanger, L. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.772057 · Cited by 8
Regadenoson Stress for Myocardial Perfusion Imaging
Reyes, E. (2015) · Future Cardiology · doi:10.2217/fca.15.70 · Cited by 8
A New Generation of Coronary Vasodilators in Stress Perfusion Imaging
Iskandrian, A. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.062 · Cited by 8
Self-citation
Update on myocardial perfusion imaging: role of regadenoson
Hendel, R. C. (2009) · Reports in Medical Imaging · doi:10.2147/rmi.s3978 · Cited by 6
Self-citation
Hemiplegic migraine episode triggered by regadenoson
Elsadany, M., McMahon, S. R., Mehla, S., & Duvall, W. L. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02736-1 · Cited by 6
Seguridad del empleo de regadenosón como fármaco vasodilatador en resonancia magnética cardíaca de estrés
Bastarrika, G., Ezponda, A., Baizán, A. G., Calvo, M., Pueyo, J. C., Gavira, J. J., & Caballeros, M. (2019) · Radiología · doi:10.1016/j.rx.2019.11.002 · Cited by 6
Patient- and clinician-reported satisfaction with pharmacological stress agents for single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Hudgens, S. A., Breeze, J. L., & Spalding, J. R. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.795488 · Cited by 6
Regadenoson in Myocardial Perfusion Study - First Institutional Experiences in Bosnia and Herzegovina
Bešlić, N., Milardović, R., Šadija, A., Cerić, Š., & Raic, Z. (2016) · Acta Informatica Medica · doi:10.5455/aim.2016.24.405-408 · Cited by 5
Safety of regadenoson for vasodilation in cardiac MRI stress tests
Bastarrika, G., Ezponda, A., Baizán, A. G., Calvo, M., Pueyo, J. C., Gavira, J. J., & Caballeros, M. (2020) · Radiología (English Edition) · doi:10.1016/j.rxeng.2020.01.002 · Cited by 5
Comparative Performances of Dipyridamole and Regadenoson to Detect Myocardial Ischemia using Cardiac Cadmium-Zinc-Telluride Single-Photon Emission Computerized Tomography
Bouallègue, F. B., Nganoa, C., Vigne, J., Agostini, D., & Manrique, A. (2018) · Journal of Clinical Imaging Science · doi:10.4103/jcis.jcis_71_17 · Cited by 5
ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson
Qamruddin, S., Huang, H. W., Mehra, A., Bonyadlou, S., & Yoon, A. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000990 · Cited by 4
Assessment of Myocardial Ischemia Using Stress Perfusion Cardiovascular Magnetic Resonance
Yamada, A., Ishida, M., Kitagawa, K., & Sakuma, H. (2018) · Cardiovascular Imaging Asia · doi:10.22468/cvia.2017.00178 · Cited by 4
Molecular modeling studies of fused pyrimidine derivatives at various receptors
Singh, P. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18616-5.00010-7 · Cited by 4
Selective action of metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs
Zhao, G., Zhang, S., Shryock, J. C., Xu, X., Ochoa, M., Hintze, T. H., & Belardinelli, L. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9481-x · Cited by 4
Nuclear cardiology: Finally a one-stop shop for diagnosis, risk stratification, and management of coronary artery disease
Cerqueira, M. D. (2009) · Clinical Cardiology · doi:10.1002/clc.4960291305 · Cited by 4
Self-citation
Pharmacologic Stress Testing
Gupta, A., Zoghbi, G. J., & Hage, F. G. (2015) · Oxford University Press eBooks · doi:10.1093/med/9780199392094.003.0010 · Cited by 4
When to re-dose regadenoson?
Thomas, G. S., Jolly, A. F., & Safani, M. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0376-0 · Cited by 4
Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas
Grossman, S. A., Romo, C. G., Ye, X., Kral, B. G., Strowd, R. E., III, Lesser, G. J., Raymond, C., Iacoboni, M., Desideri, S., Fisher, J. D., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf041 · Cited by 3
Extracellular ATP and structurally related molecules potentiate adenosine A2a receptor-stimulated cAMP production
Wang, F. I., Dixon, S. J., & Chidiac, P. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111711 · Cited by 3
Arrhythmias in vasodilator stress testing
Subbiah, R., & Patil, P. V. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0407-5 · Cited by 3
Regadenoson-induced hyperemia for absolute myocardial blood flow quantitation by 13N-ammonia PET and detection of cardiac allograft vasculopathy
Packard, R. R. S., & Maddahi, J. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0763-1 · Cited by 3
Synthetic Small-Molecule Ligands Targeted to Adenosine Receptors: Is There Potential Towards Ischemic Heart Disease?
Xu, Q., Opoku, Y. N., Authi, K. S., & Cilibrizzi, A. (2025) · Cells · doi:10.3390/cells14151219 · Cited by 2
Regadenoson for myocardial perfusion scintigraphy
Reyes, E., & Pennell, D. J. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.506909 · Cited by 2
QTc prolongation after regadenoson administration
Gupta, A., Borer, S. M., & Heller, G. V. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9589-7 · Cited by 2
Development and validation of a hydrophilic interaction liquid chromatography‐tandem mass spectrometry method for the quantification of regadenoson in human plasma and its pharmacokinetic application
Wang, D., Wang, D., Fang, Q., Ye, S., Zeng, N., Yang, Y., Zhang, H., Wang, Y., & Sun, L. (2022) · Journal of Separation Science · doi:10.1002/jssc.202100756 · Cited by 2
The Editor's Roundtable: Advances in Myocardial Perfusion Imaging
Friedewald, V. E., Iskandrian, A. E., Mahmarian, J. J., & Roberts, W. C. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.12.004 · Cited by 2
Self-citation
Adenosine–caffeine: the agonist—antagonist couple for vasodilator stress tests
Songy, B. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-03107-0 · Cited by 2
2026 American Society of Nuclear Cardiology guideline for stress testing in single-photon emission computed tomography and positron emission tomography myocardial perfusion imaging
Duvall, W. L., Skali, H., Aggarwal, N. R., Boczar, K. E., Calnon, D. A., Chareonthaitawee, P., Doukky, R., Einstein, A. J., Hage, F. G., Hutt, E., et al. (2026) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2026.102970 · Cited by 1

Authors: Hendel, R. C., Bateman, T. M., Cerqueira, M. D., Iskandrian, A. E., Leppo, J. A., Blackburn, B., & Mahmarian, J. J.
Affiliations: Rush University Medical Center (US)
Cleveland Clinic (US)
University of Alabama at Birmingham (US)
Berkshire Medical Center (US)
Houston Methodist (US)
Corresponding author: Hendel, Robert C.
ORCID: Hendel, Robert C.
Bateman, Timothy M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-12
Volume: 46
Issue: 11
Pages: 2069-2075
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.05.097
OpenAlex: W1984550508
Cited by: 128
References: 17
Citations by year: 2026: 2 · 2025: 3 · 2024: 3 · 2022: 5 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 10 · 2014: 4 · 2013: 9 · 2012: 12
FWCI: 6.13
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2821 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: regadenoson, adenosine A2A receptor agonist, pharmacological stress, myocardial perfusion imaging, SPECT, drug tolerability, adverse effects, coronary artery disease
MeSH terms: Adenosine, Electrocardiography, Heart, Humans, Organophosphorus Compounds, Pilot Projects, Purines, Pyrazoles, Organotechnetium Compounds, Tomography, Emission-Computed, Single-Photon, Myocardial Ischemia, Technetium Tc 99m Sestamibi, Radiopharmaceuticals, Adenosine A2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Initial Clinical Experience With Regadenoson, a Novel Selective A2AAgonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks